Ocuphire Pharma shares are trading higher after HC Wainwright & Co initiated coverage on the stock with a Buy rating and a $26 price target. The company yesterday announced the first subjects have been enrolled in the MIRA-3 Phase 3 pivotal trial evaluating Nyxol Eye Drops in the reversal of pharmacologically-induced mydriasis.